Sanara MedTech (SMTI) AI Stock Analysis

• Market Cap: $299.56M
• Dividend Yield: N/A
• Average Volume (3M): 44.92K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.06
• Revenue Growth: 34.29%
• EPS Growth: -49.21%
• Country: US
• Employees: 141
• Sector: Healthcare
• Sector Strength: 47
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.23
• Shares Outstanding: 8,902,351
• 10 Day Avg. Volume: 51,320
• 30 Day Avg. Volume: 44,925
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.91
• Enterprise Value/Revenue: 2.81
• Enterprise Value/Gross Profit: 3.10
• Enterprise Value/Ebitda: 194.79
• 1Y Price Target: $49.50
• Price Target Upside: 45.85% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 58 Neutral
• Price Target: $33.00 ▼(-2.77% Downside)

Sanara MedTech's overall stock score is driven by strong technical indicators, suggesting bullish momentum, and robust revenue growth in the Surgical segment. However, significant profitability and cash flow challenges, along with a negative P/E ratio, weigh down the score. The company's reliance on debt financing and the ongoing losses in the THP segment add further risk.

Positive Factors

Earnings

Sanara MedTech reported a net revenue of $25.8M in 2Q25, showing 28% year-over-year growth and surpassing projections.

Product Demand

Revenue for soft tissue repair products increased by 28% year-over-year, driven by demand for CellerateRX Surgical Activated Collagen.

Negative Factors

Debt Obligations

The company has $44.2M of principal debt obligations, indicating a significant financial commitment.

Financial Risks

Risks include lower-than-projected revenue growth of products and services, inability to secure additional customers, inability to launch new products or services, and potential dilution risk.

Sanara MedTech Business Overview & Revenue Model

Company Description

Sanara MedTech Inc. (SMTI) is a medical technology company focused on developing and commercializing advanced wound care products and regenerative medicine solutions. The company operates primarily in the healthcare sector, providing innovative treatment options that enhance healing processes for patients suffering from chronic wounds and other medical conditions. Sanara's core products include bioengineered wound care solutions and various medical devices that promote tissue regeneration and healing.

How the Company Makes Money

Sanara MedTech generates revenue through the sale of its proprietary wound care and regenerative medicine products, which are marketed to hospitals, clinics, and healthcare providers. The company utilizes a direct sales force and distribution partnerships to reach its target markets effectively. Key revenue streams include product sales, licensing agreements, and potentially reimbursement from insurance providers for its medical solutions. Strategic partnerships with healthcare institutions and organizations also enhance its market presence and contribute to its earnings, as they may involve collaborative research, co-marketing arrangements, or joint ventures that expand the company's product offerings and market access.

Sanara MedTech Financial Statement Overview

Summary

Sanara MedTech shows strong revenue growth and a high gross profit margin, but faces challenges with profitability, cash flow, and increased debt reliance. These financial risks need addressing for long-term stability.

Income Statement

Sanara MedTech has shown a positive revenue growth rate of 6.19% in the TTM, indicating a healthy expansion in sales. The gross profit margin is strong at 91.76%, reflecting efficient cost management. However, the company is facing profitability challenges with a negative net profit margin of -10.22% and negative EBIT margin, indicating operational inefficiencies.

Balance Sheet

The company's debt-to-equity ratio has increased to 1.28 in the TTM, suggesting a higher reliance on debt financing, which could pose a risk if not managed carefully. The return on equity is negative, indicating that the company is not generating profits from shareholders' equity. The equity ratio is moderate, showing a balanced asset financing structure.

Cash Flow

The free cash flow growth rate is significantly negative at -102.55%, indicating cash flow challenges. The operating cash flow to net income ratio is low at 0.25, suggesting limited cash generation from operations relative to net income. The free cash flow to net income ratio is also low, pointing to potential liquidity issues.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	97.24M	86.67M	64.99M	45.84M	24.14M	15.59M
Gross Profit	88.11M	78.53M	57.14M	39.48M	21.83M	13.97M
EBITDA	1.40M	-1.86M	-289.10K	-9.67M	-7.22M	-4.02M
Net Income	-9.94M	-9.66M	-4.30M	-7.94M	-7.92M	-4.36M
Balance Sheet
Total Assets	98.77M	88.09M	73.87M	61.04M	36.40M	9.83M
Cash, Cash Equivalents and Short-Term Investments	16.96M	15.88M	5.15M	8.96M	18.65M	455.37K
Total Debt	45.45M	32.29M	11.79M	819.22K	425.44K	481.38K
Total Liabilities	63.38M	49.18M	29.28M	19.32M	6.24M	3.99M
Stockholders Equity	35.40M	39.40M	44.83M	41.83M	30.64M	6.15M
Cash Flow
Free Cash Flow	58.91K	-229.63K	-3.51M	-6.30M	-5.56M	-5.68M
Operating Cash Flow	3.65M	-23.78K	-3.25M	-5.55M	-4.81M	-4.03M
Investing Cash Flow	-15.59M	-6.61M	-10.21M	-3.51M	-5.28M	-2.74M
Financing Cash Flow	22.76M	17.37M	9.64M	-627.35K	28.30M	622.33K

Sanara MedTech Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 33.94
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SMTI, the sentiment is Positive. The current price of 33.94 is above the 20-day moving average (MA) of 28.79, above the 50-day MA of 28.20, and above the 200-day MA of 31.80, indicating a bullish trend. The MACD of 1.74 indicates Negative momentum. The RSI at 67.79 is Neutral, neither overbought nor oversold. The STOCH value of 81.39 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SMTI.

Sanara MedTech Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
UTMD	77 Outperform	$194.72M	16.14	10.39%	1.99%	-16.64%	-13.64%
PDEX	75 Outperform	$152.32M	16.69	28.29%	―	29.65%	131.78%
STXS	66 Neutral	$252.02M	―	-198.62%	―	33.94%	-6.91%
SMTI	58 Neutral	$299.56M	―	-25.78%	―	34.29%	-49.21%
OSUR	57 Neutral	$254.52M	25.27	-12.65%	―	-49.35%	-285.61%
ANGO	55 Neutral	$397.81M	―	-17.50%	―	-3.76%	81.78%
Sector *	51 Neutral	$7.83B	-0.18	-40.10%	2.29%	21.46%	-2.03%

Sanara MedTech Corporate Events

Sanara MedTech Updates Investor Presentation Online

On May 22, 2025, Sanara MedTech Inc. held its Annual Meeting of Shareholders, where a total of 6,781,075 shares were represented. During the meeting, the election of eight directors to the Board and the ratification of Weaver and Tidwell, L.L.P. as the independent registered public accounting firm for the fiscal year ending December 31, 2025, were approved by the shareholders. Additionally, on May 27, 2025, the company updated its investor presentation on its website, emphasizing the importance of monitoring their Investor Relations section for material information.

Sanara MedTech’s CAO Michael McNeil Announces Retirement

On May 19, 2025, Michael D. McNeil announced his retirement from his roles as Chief Accounting Officer and Chief Administrative Officer at Sanara MedTech Inc., effective August 19, 2025. The company is in discussions with McNeil for a consulting role to aid in the transition. Elizabeth B. Taylor, the current Chief Financial Officer, will take over McNeil’s responsibilities as the principal accounting officer.